Myelin breakdown in Alzheimer's disease: A commentary

Neurobiology of Aging

Volumn 25, Issue 1, 2004, Pages 45-47

  Connor, James R ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CHOLESTEROL; CUPRIZONE; GAMMA INTERFERON; HYPOCHOLESTEROLEMIC AGENT; INTERLEUKIN 1BETA; IRON; IRON CHELATING AGENT; MYELIN; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA;

AEROBIC METABOLISM; AGING; ALZHEIMER DISEASE; CHOLESTEROL SYNTHESIS; DEMYELINATION; HUMAN; IRON METABOLISM; MEMORY CONSOLIDATION; MULTIPLE SCLEROSIS; NONHUMAN; NOTE; OLIGODENDROGLIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; WHITE MATTER;

EID: 0348111547     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2003.06.004     Document Type: Note

References (32)

1. Baerwald K.D., Popko B. Developing and mature oligodendrocytes respond differently to the immune cytokine interferon-gamma. J. Neurosci. Res. 52:1998;230-239.
2. Bartlett W.P., Li X.S., Connor J.R. Expression of transferrin mRNA in the CNS of normal and jimpy mice. J. Neurochem. 57(1):1991;318-322.
3. Bowern N., Ramshaw I.A., Clark I.A., Doherty P.C. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J. Exp. Med. 160:1984;1532-1543.
4. Butt A.M., Jenkins H.G. Morphological changes in oligodendrocytes in the intact mouse optic nerve following intravitreal injection of tumor necrosis factor. J. Immunol. 51:1994;27-33.
5. Cammer W. Oligodendrocyte associated enzymes. In: Norton WT, editor. Oligodendroglia. New York: Plenum Press; 1984. p. 199-232.
6. Cheepsunthorn P., Radov L., Menzies S., Reid J., Connor J.R. Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia. 35(1):2001;53-62.
7. Connor J.R., Menzies S.L. Relationship of iron to oligodendrocytes and myelination. Glia. 17:1996;83-93.
8. Connor J.R., Phillips T.M., Lakshman M.R., Barron K.D., Fine R.E., Csiza C.K. Regional variation in the levels of transferrin in the central nervous system of normal and myelin-deficient rats. J. Neurochem. 49:1987;1523-1529.
9. Connor J.R., Snyder B.S., Beard J.L., Fine R.E., Mufson E.J. The regional distribution of transferrin, ferritin and iron in aging and Alzheimer's diseased brain. J. Neurosci. Res. 31:1992;327-335.
10. Corbin J.G., Kelly D., Rath E.M., Baerwald K.D., Suzuki K., Popko B. Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol. Cell. Neurosci. 7:1996;354-370.
11. de Arriba Zerpa G.A., Saleh M.C., Fernandez P.M., Guillou F., Espinosa de los Monteros A., de Vellis J.et al. Alternative splicing prevents transferrin secretion during differentiation of a human oligodendrocyte cell line. J. Neurosci. Res. 61(4):2000;388-395.
12. Fahmy M., Young S.P. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: changes in transferrin uptake, iron handling and ferritin mRNA. Biochem. J. 296:1993;175-181.
13. Feelders R.A., Vreugdenhill G., Eggermont A.M.M., Kuiper-Kramer P.A., van Eijk H.G., Swaak A.J.G. Regulation of iron metabolism in the acute-phase response: interferon γ and tumour necrosis factor α induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur. J. Clin. Invest. 28:1998;520-527.
14. Halliwell B., Gutteridge J.M.C., Cross C.E. Free radicals, antioxidants and human disease: where are we now? J. Lab. Clin. Med. 119:1992;598-620.
15. Hiremath M.M., Saito Y., Knapp G.W., Ting J.P.Y., Suzuki K., Matsushima G. J. Neuroimmunol. 92:1998;38-49.
16. Leeden R.W., Chakraborty G. Cytokines signal transduction and inflammatory demyelination: review and hypothesis. Neurochem. Res. 23:1998;277-289.
17. Levine S.M., Lynch S.G., Ou C.-N., Wulser M.J., Tam E., Boo N. Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res. 821:1999;511-515.
18. Louis J.C., Magal E., Muir D., Manthorpe M., Varon S. CG-4, a new bipotential glial cell line from rat brain is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J. Neurosci. Res. 31:1992;193-204.
19. Malecki E., Connor J.R. The case for iron chelation and/or antioxidant therapy in Alzheimer's disease. Drug Dev. Res. 56(3):2002;526-530.
20. Merrill J.E., Benveniste E.N. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci. 19:1996;331-338.
21. Miller L.L., Miller S.C., Torti S.V., Tsuji Y., Torti F.M. Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc. Natl. Acad. Sci. U.S.A. 88:1991;4946-4950.
22. Morell P., Barrett C.V., Mason J.L., Toews A.D., Hostettler J.D., Knapp G.W.et al. Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol. Cell. Neurosci. 12:1998;220-227.
23. Morell P, Quarles RH, Norton WT. Myelin formation, structure and biochemistry. In: Seigel GJ, et al., editors. Basic neurochemistry: molecular, cellular and medical aspects, 5th ed. New York: Raven Press; 1994.
24. Pinero D.J., Hu J., Cook B., Connor J.R. Interleukin-1beta increases binding of the iron regulatory protein and the synthesis of ferritin by increasing the labile iron pool. Biochim. Biophys. Acta. 1497:2000;279-288.
25. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α Proc. Natl. Acad. Sci. U.S.A. 92:1995;11294-11298.
26. Selmaj K.W., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:1988;339-346.
27. Simmons R.D., Willenborg D.O. Direct injection of cytokines into the spinal cord causes autoimmune encephalomyelitis-like inflammation. J. Neurol. Sci. 100:1990;37-42.
28. Smirnov I.M., Bailey K., Flowers C.H., Garrigues N.W., Wesselius L.J. Effects of TNF-α and IL-1β on iron metabolism by A459 cells and influence on cytotoxicity. Am. J. Physiol. 277:1999;L257-L263.
29. Tansey F.A., Zhang H., Cammer W. Expression of carbonic anhydrase II mRNA and protein in oligodendrocytes during toxic demyelination in the young adult mouse. Neurochem. Res. 21:1996;411-416.
30. Traugott U., Lebon P. Demonstration of α, β and γ interferon in active chronic multiple sclerosis lesions. Ann. N.Y. Acad. Sci. 540:1988;309-311.
31. Wagner-Recio M., Toews A.D., Morell P. Tellurium blocks cholersterol synthesis by inhibiting squlaene metabolism: preferential vulnerability to this metabolic block leads to peripheral nervous system demyelination. J. Neurochem. 57:1991;1891.
32. Ye P., D'Ercole A.J. Insulin-like growth factor I protects oligodendrocytes from tumor necrosis factor-α-induced injury. Endocrinology. 140:1999;3063-3072.